We’ve known for a while that there are two Anguses—both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the first time, we’re bringing them together for a “Variety Studio: Actors on Actors”-style conversation.

In this week’s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu and STAT Cancer Reporter Angus Chen share insights into their work covering cancer and their thoughts on racial identity during a tumultuous time.

They discuss what excites them most in the oncology field, how their reporting approaches differ and how they’ve often been mistaken for one another.

To learn more about the topics in this episode: 
Judge permanently blocks NIH grant caps, prompting HHS appeal
Cancer research, long protected, feels ‘devastating’ effects under Trump
As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says

We&rsquo;ve known for a while that there are two Anguses&mdash;both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the first time, we&rsquo;re bringing them together for a &ldquo;Variety Studio: Actors on Actors&rdquo;-style conversation.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu and STAT Cancer Reporter Angus Chen share insights into their work covering cancer and their thoughts on racial identity during a tumultuous time.
They discuss what excites them most in the oncology field, how their reporting approaches differ and how they&rsquo;ve often been mistaken for one another.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/judge-permanently-blocks-nih-grant-caps-decision-hhs-appealing">Judge permanently blocks NIH grant caps, prompting HHS appeal</a></li>
<li><a href="https://www.statnews.com/2025/03/24/trump-cancer-research-funding-cuts-patients-researchers-worried/">Cancer research, long protected, feels &lsquo;devastating&rsquo; effects under Trump</a></li>
<li><a href="https://www.fiercebiotech.com/cro/trump-targets-dei-4-pharmas-reaffirm-commitments-diversifying-clinical-trials">As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials</a></li>
<li><a href="https://www.fiercepharma.com/pharma/cell-and-gene-therapies-peter-marks-fda-exit-jolts-struggling-field-deep-uncertainty">For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty</a></li>
<li><a href="https://www.statnews.com/2025/01/31/car-t-cells-donate-protein-other-immune-cells-to-fight-cancer-study/">CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement